“exelixis” Archives

Entry Author Date Location
OncoGenex Waits, and Waits, For Data on Prostate Cancer Drug 08/02/12 Seattle
ASCO Wrap-Up: A Summary of This Week’s Cancer R&D Headlines 06/05/12 National
ASCO Preview: Eight Cancer Drugs to Watch at the Big Show 05/14/12 National
OncoGenex Snags $50M for Prostate Cancer Drug Plan 03/16/12 Seattle
OncoGenex Doubles Down on Prostate Cancer, As Competition Heats Up 03/08/12 Seattle
Bruce Booth, a LifeSciVC Shining Some Much-Needed Light on Biotech 02/27/12 National
Groupon: The IPO With More Sizzle, and Money, Than the Entire Biotech IPO Class of 2011 11/07/11 National
Exelixis To Push Ahead on Prostate Cancer Trial Without FDA Agreement: Shares Plunge 10/31/11 San Francisco
Exelixis Passes Key Test With Lead Drug; Stock Soars 10/24/11 San Francisco
What Most Biotechies Are Missing on Twitter: A Huge Networking Opportunity 09/12/11 National
George Scangos, the Boy From Working Class Boston, on His Road Back to Lead Biogen Idec 08/31/11 Boston
Encouraged by Early Work on Anti-Cancer Drug, Intellikine Hires New Head for Clinical Trials 07/18/11 San Diego
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent 07/18/11 National
iPierian Shakeup Continues, as Chairman Corey Goodman, Scientist Doug Melton Exit Stem Cell Startup 06/15/11 San Francisco
ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S. 06/07/11 National
Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients 06/06/11 San Francisco
The Quest For Biotech Independence: Maybe It Isn’t So Quixotic After All 06/06/11 National
FivePrime Nabs Partner, Solazyme’s $100M IPO Plan, Where Blockbuster Drugs Come From, & More Bay Area Life Sciences News 03/18/11 San Francisco
Exelixis Tacks on $23M 03/15/11 San Francisco
Exelixis Bags $156M, Tethys Bets on Prevention, UCSF’s Delicate Dance With Industry, & More Bay Area Life Sciences News 03/11/11 San Francisco
Exelixis Pockets $156M in Stock Sale, Riding Wave of Prostate Cancer Drug Results 03/09/11 San Francisco
Big Pharma’s Hardball Tactics Won’t Kill Biotech, But They Could Kill Off Some Pharmas 02/28/11 National
Testing Experimental Drugs in Combination – A New Trend 12/22/10 San Diego
Roche Cutting Hundreds of Jobs, Exelixis Shares Soar, Sutro Pockets $36.5M, & More Bay Area Life Sciences News 11/19/10 San Francisco
Exelixis Shares Soar on Cancer Results 11/18/10 San Francisco
Biogen Idec Axes 650 Jobs, Closes San Diego Site, Bets Future on Neurology 11/03/10 Boston
Exelixis Seeks to Exit Doghouse, Sangamo Morphs Into Drugmaker, Siluria Adds $13M, & More Bay Area Life Sciences News 10/22/10 San Francisco
Exelixis Seeks to Climb From the Penalty Box, Prove its Lead Drug Still Has Legs 10/20/10 San Francisco
Exelixis Gets $60M from Bristol, Genentech Surpasses Original Herceptin, Synosia Pockets $30M, & More Bay Area Life Sciences News 10/15/10 San Francisco
Exelixis Nabs $60M Upfront, Potentially $505M More, From New Deal With Bristol-Myers 10/11/10 San Francisco
Page 2 of 3 « previous page · next page »